Another day, another lawsuit reminder
Gossamer Bio is getting the kind of inbox spam nobody wants: a securities class-action reminder. Faruqi & Faruqi says investors who bought Gossamer shares between June 16, 2025 and February 20, 2026 may want to get in touch before the June 1, 2026 deadline to seek lead-plaintiff status.
Why investors should care
This isn’t just legal theater. Class-action chatter can keep pressure on a biotech stock already dealing with enough uncertainty, because it raises the possibility of more distraction, more legal costs, and more headline risk. If you’re a shareholder, you don’t need a law degree to know that’s not exactly a bullish combo.
The bottom line
The filing doesn’t mean Gossamer has been found liable — not yet, anyway. But it does mean the stock has another overhang hanging around like a sequel nobody asked for. Big picture: when the lawyers keep calling, investors usually keep squinting at the chart.
